Grunenthal
Grünenthal is a privately held, family-owned pharmaceutical company headquartered in Aachen, Germany, specializing in pain therapeutics. It sells the non-opioid Qutenza® patch and opioid Palexia® formulations to physicians and hospitals across approximately 100 countries via owned subsidiaries and licensing partnerships.
- Company typePrivate
- Founded1946
- HeadquartersAachen, Germany
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Grunenthal does
Grünenthal is a privately held, research-focused pharmaceutical company headquartered in Aachen, Germany, specializing in pain management and related diseases. Founded in 1946 and family-controlled by the Wirtz family, the company employs approximately 4,400 people and operates through subsidiaries in 28 countries, with products available in approximately 100 countries. Its commercial portfolio centers on Qutenza®, a topical non-systemic, non-opioid capsaicin 8% patch for peripheral neuropathic pain (acquired in 2018), and Palexia® (tapentadol), an opioid analgesic available in multiple formulations including extended-release tablets and oral solutions. Supporting the commercial franchise are educational and professional services platforms — Grünenthal Campus (product information and study summaries for healthcare professionals) and Grünenthal PRO — together with co-sponsorship of long-standing pain research and palliative care awards with Deutsche Schmerzgesellschaft (since 1987) and Deutsche Gesellschaft für Palliativmedizin (since 2008).
Grünenthal generates revenue through pharmaceutical product sales across both opioid and non-opioid pain treatments, supplemented by international licensing partnerships that extend its reach into geographies without owned sales infrastructure. Distribution is conducted primarily through physician prescriptions, hospital pharmacies, and direct field sales to healthcare providers in the DACH region, Europe, Latin America, and the United States, with selective licensing agreements (such as the recent Clinect Pty Ltd arrangement for Qutenza® in Australia) covering additional markets. The company has historically pursued an M&A-driven growth strategy, exemplified by the 2018 Qutenza® acquisition and a past $11.75 billion joint bid with EQT for Organon & Co., and actively defends its intellectual property through regulatory and legal actions, including a December 2022 German injunction against generic Palexia® retard competitors.
Grünenthal reported revenue of €1.7 billion in 2022 with double-digit revenue growth and record sales announced for 2023. Beyond its commercial activities, the company maintains scientific partnerships, a Global Graduate Programme, and sustainability initiatives such as a 1.9 MWp solar installation at its Aachen campus commissioned in 2024. The company is recognized as a Great Place to Work employer in Germany and is a member of EFPIA and the Vfa.
Grunenthal firmographics
Firmographics- Name
- Grunenthal
- Legal name
- Grünenthal GmbH
- Website
- https://grunenthal.de
- Company type
- Private
- Founded year
- 1946
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Grünenthal is a privately held, family-owned pharmaceutical company headquartered in Aachen, Germany, specializing in pain therapeutics. It sells the non-opioid Qutenza® patch and opioid Palexia® formulations to physicians and hospitals across approximately 100 countries via owned subsidiaries and licensing partnerships.
- Ownership category
- akta.pro rank
Grunenthal industry classification
Industry- Product category
- Pain Management Pharmaceuticals
- NAICS
- Ophthalmic Goods Manufacturing (339115), Ophthalmic Goods Merchant Wholesalers (423460)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Ophthalmic & Otic Generics (HLAIABAF)
- akta.pro secondary industry
- Ophthalmology Pharmaceuticals (HLAIAAAL)
Keywords
Where Grunenthal is headquartered
LocationHeadquarters
- HQ city
- Aachen
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
Grunenthal business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: Grünenthal generates revenue through the development, manufacturing, and sale of pharmaceutical products, primarily focused on pain treatments and related conditions. The company reported revenue of 1.7 billion euros in 2022 with double-digit revenue growth.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Pharmaceutical prescription products distributed through healthcare providers and pharmacies |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Grunenthal product offering
Product offeringCore offering
Grünenthal is a research-focused pharmaceutical company that develops, manufactures, and commercializes prescription medications for pain management and related conditions. Its core commercial products are Qutenza®, a topical non-systemic, non-opioid capsaicin patch for peripheral neuropathic pain, and Palexia®, an opioid analgesic (tapentadol) available in extended-release and oral solution formulations. The company also operates healthcare-professional education and service platforms (Grünenthal Campus, Grünenthal PRO) supporting product adoption.
Product overview
Grünenthal is a research-focused pharmaceutical company specializing in pain treatment and related conditions. The company's product portfolio includes Qutenza® (topical non-opioid patch for neuropathic pain, acquired in 2018), Palexia® (opioid analgesic in extended-release and oral formulations), and supporting platforms like Grünenthal Campus for healthcare professional education. The company operates primarily in Europe with products available in approximately 100 countries.
Differentiator
Problem solved
Functional benefit
Products and services
- Qutenza® Topical, non-systemic, non-opioid capsaicin patch indicated for the management of peripheral neuropathic pain. Distributed via physician prescription to healthcare providers and hospitals.
- Palexia® retard
Quantifiable outcome
- Record revenue of 1.7 billion EUR with double-digit growth in 2023
Companies that use Grunenthal
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
Grunenthal technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Grunenthal partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Clinect Pty LtdcoreGrünenthal entered into a definitive agreement granting Clinect Pty Ltd exclusive Australian rights to Qutenza®, a topical non-systemic, non-opioid patch for peripheral neuropathic pain. Clinect is responsible for obtaining marketing authorisation in Australia and will handle marketing and distribution of the product. This aligns with Grünenthal's strategy to expand the global footprint of Qutenza®.
- Deutsche Schmerzgesellschaft e.V. (German Pain Society)coreLong-standing partnership since 1987 where Grünenthal co-sponsors the annual Förderpreis für Schmerzforschung (Pain Research Funding Award). This partnership supports scientific work in applied and translational pain research.
- Deutsche Gesellschaft für Palliativmedizin (DGP)coreSince 2008, Grünenthal co-sponsors the Anerkennungs- und Förderpreis für Praxisinitiativen in der Palliativversorgung (Recognition and Funding Award for Palliative Care Initiatives) endowed with 10,000 euros.
- Solarimo GmbHminorSolarimo GmbH built and operates the largest solar installation in Aachen on Grünenthal's campus property. The approximately 4,000 solar modules with 1.9 MWp capacity will generate renewable energy and help Grünenthal achieve its 2030 carbon reduction targets.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
Grunenthal competitors and assessment
Company assessmentDirect peers
- Mundipharma International: Mundipharma is a privately-held specialty pharmaceutical company focused on pain management and related therapies across global markets. It is one of the closest direct comparables to Grünenthal given the shared pain-focused portfolio, private ownership structure, and international commercialization footprint.
- Purdue Pharma: Purdue Pharma was a pain-management specialist built around opioid and non-opioid analgesics before its restructuring. Its product portfolio, prescriber relationships, and historical regulatory exposure make it a directly comparable, albeit cautionary, peer for Grünenthal's pain franchise.
- Collegium Pharmaceutical: Collegium Pharmaceutical is a US specialty pharma focused on responsible pain management, including abuse-deterrent formulations. Its pain-only focus and similar GTM targeting of pain specialists and prescribers make it a directly comparable peer in scale and strategy.
- Mallinckrodt plc: Mallinckrodt is a specialty pharmaceutical company with a significant branded pain portfolio and hospital-channel distribution. Overlap in therapeutic focus, prescriber base, and product types makes it a strong comparable to Grünenthal.
- Endo International: Endo International built a pain-focused specialty pharma franchise around branded and generic analgesics. The therapeutic overlap and US-centric commercialization approach make it directly comparable to Grünenthal's pain business, particularly around the Palexia franchise.
Regional players
- Aché Laboratórios Farmacêuticos: Aché is a leading Brazilian pharmaceutical company with a meaningful pain and analgesic portfolio across Latin America. It is a regional peer in the same therapeutic category but serves primarily Latin American markets rather than competing directly in Europe.
Broad incumbents
- Daiichi Sankyo: Daiichi Sankyo is a major Japanese pharmaceutical company with established pain and analgesic product lines alongside broader therapeutic areas. Its pain portfolio offers a broad-incumbent comparable to Grünenthal's specialty focus.
- Teva Pharmaceutical Industries: Teva is a global pharmaceutical company with a large specialty and generics portfolio that includes pain medications. Comparable as a broad-incumbent player with overlapping pain therapy offerings and global commercialization capabilities.
Market position
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Grunenthal social profiles
Digital presenceGrunenthal financial estimates
Financial estimateRevenue estimate
Valuation estimate
Grunenthal leadership team
Management profileNumber of profiles
Profiles6 records
Grunenthal funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Grunenthal M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Grunenthal
What does Grunenthal do?
Grünenthal is a research-focused pharmaceutical company that develops, manufactures, and commercializes prescription medications for pain management and related conditions. Its core commercial products are Qutenza®, a topical non-systemic, non-opioid capsaicin patch for peripheral neuropathic pain, and Palexia®, an opioid analgesic (tapentadol) available in extended-release and oral solution formulations. The company also operates healthcare-professional education and service platforms (Grünenthal Campus, Grünenthal PRO) supporting product adoption.
Is Grunenthal a public or private company?
Grunenthal is a private company. It is classified as family owned and is currently operating.
When was Grunenthal founded?
Grunenthal was founded in 1946. It employs 1,001 to 5,000 people.
Where is Grunenthal based?
Grunenthal is headquartered in Aachen, Germany, in the Europe region.
How does Grunenthal make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Grunenthal's main competitors?
Direct peers on record are Mundipharma International, Purdue Pharma, Collegium Pharmaceutical, Mallinckrodt plc and Endo International. Aché Laboratórios Farmacêuticos is listed as a regional player. Broad incumbents are Daiichi Sankyo and Teva Pharmaceutical Industries.
Does Grunenthal have an API?
No public API is recorded for Grunenthal.
What industry is Grunenthal in?
Grunenthal's product category is Pain Management Pharmaceuticals. Its primary akta.pro industry code is HLAIABAF, Ophthalmic & Otic Generics, with a secondary code of HLAIAAAL, Ophthalmology Pharmaceuticals. Its NAICS code is 339115 and its SIC code is 3841.